$MCK

Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks

McKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.

Original reporting
Published Aug 19, 2026, 12:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Winners And Losers Of Q2: McKesson (NYSE:MCK) Vs The Rest Of The Healthcare Providers & Services Stocks — source image
Decision brief

The 30-second read

$MCKBearishMed
01

Why it matters

Earnings releases cause varied price moves, highlighting sector rotation.

02

Market read

Earnings-driven price swings provide short‑term trading opportunities across the healthcare services space.

03

What to watch

Member loss at ELV may be temporary; AHCO's revenue growth still outpaces peers.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Quarterly earnings season for healthcare providers and services.

Company-level read

Ticker impact

$MCKBearishHigh confidence
Context

Q2 earnings released; stock down 9.1% since report.

Expected impact

Potential further downside if guidance remains weak.

Evidence & confidence

Revenue and earnings fell short of expectations, prompting a 9% drop.

$AHCOBearishHigh confidence
Context

Q2 earnings released; stock down 46.2% since report.

Expected impact

Likely continued pressure unless guidance improves.

Evidence & confidence

Revenue up 12.7% YoY but missed estimates; full‑year guidance also missed, driving a large decline.

$ELVBearishMedium confidence
Context

Q2 earnings released; stock down 7.4% since report.

Expected impact

Modest further downside expected.

Evidence & confidence

Revenue flat, slight EPS beat, but member loss signals weaker future growth.

$DGXBullishHigh confidence
Context

Q2 earnings released; stock up 12.6% since report.

Expected impact

Potential upside continuation if guidance stays strong.

Evidence & confidence

Revenue up 10.2% YoY and beat estimates, leading to a double‑digit gain.

Market effects

Healthcare services sector shows divergent performance across peers.

U.S. healthcare stocks may see broader volatility.

Limited to U.S. markets; no direct global macro link.

Counterpoint

Despite broad sector weakness, DGX's strong beat could signal a buying opportunity.

Key entities

  • McKesson

    Healthcare distribution giant.

  • AdaptHealth

    Home medical equipment provider.

  • Elevance Health

    Health insurer.

  • Quest Diagnostics

    Diagnostic testing services.

Related articles

$RDNTHighAI 8/10

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

Guardant Health, RadNet (NASDAQ:RDNT), Labcorp (NYSE:LH), NeoGenomics (NASDAQ:NEO), and Quest (NYSE:DGX) reported Q2 results. RadNet saw 25% revenue growth, beating estimates. Labcorp's revenue grew 5.8%, meeting expectations but underperforming peers. NeoGenomics and Quest both beat estimates with 11.2% and 10.2% revenue growth, respectively. Stocks have risen since reporting.

$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

$ELVHighAI 8/10

Why is Elevance Health stock surging today?

Elevance Health (ELV) stock rose 5.8% to $418.21 after reaffirming its 2026 adjusted earnings guidance of at least $27.00 per share and signaling Q3 EPS is tracking ahead of expectations. The company also maintained its 2026 operating cash flow target of $6 billion and a 12% adjusted EPS growth target for 2027. Today is the ex-dividend date for its $1.72 per share quarterly dividend.